Evidence map›Paper›PMID 37403517›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2023

Novel pyrimidine Schiff bases and their selenium-containing nanoparticles as dual inhibitors of CDK1 and tubulin polymerase: design, synthesis, anti-proliferative evaluation, and molecular modelling.

Samar El-Kalyoubi, Samiha A El-Sebaey, Ahmed A El-Sayed, Moustafa S Abdelhamid, Fatimah Agili, Sherin M Elfeky

Abstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Samar El-KalyoubiDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Port Said University, Port Said, Egypt.ORCID 0000-0002-4648-5184
Samiha A El-SebaeyDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.ORCID 0000-0002-9928-9080
Ahmed A El-SayedPhotochemistry Department, Chemical Industries Research Institute, National Research Centre, Giza, Egypt.
Moustafa S AbdelhamidDepartment of Biochemistry, Faculty of Science, Zagazig University, Zagazig, Egypt.
Fatimah AgiliChemistry Department, Faculty of Science (Female Section), Jazan University, Jazan, Saudi Arabia.
Sherin M ElfekyDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology-based strategies can overcome the limitations of conventional cancer therapies. Hence, novel series of pyrimidine Schiff bases (

Indexed as

Antineoplastic AgentsSeleniumCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorMolecular Docking SimulationMolecular StructurePyrimidinesSchiff BasesStructure-Activity RelationshipTubulinAntineoplastic AgentsPyrimidinesSchiff BasesSeleniumTubulinAnti-proliferativecyclin-dependent kinase 1pyrimidineselenium nanoparticlestubulin polymerase

Identifiers

PMID37403517
PMCPMC10324454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.